« Back to Infections and Infestations

Hansen’s Disease (Leprosy)

»	What causes leprosy?
»	Why is leprosy called Hansen’s disease?
»	How is leprosy transmitted?
»	Are children and adults equally susceptible to acquiring leprosy?
»	Are humans the only host for M. leprae?
»	Is leprosy a systemic disease?
»	How common is leprosy?
»	Are there endemic areas for leprosy in the United States?
»	How is leprosy recognized clinically?
»	Is there more than one kind of leprosy?
»	Does indeterminate leprosy mean that you do not know what type it is?
»	What are the two “polar” forms of leprosy? How do they differ?
»	Describe dimorphous leprosy.
»	What is the unusual feature of the cell-mediated immunity in lepromatous leprosy?
»	Define the cytokine response to M. leprae in tuberculoid versus lepromatous patients.
»	How is the diagnosis of leprosy usually made?
»	What area should be biopsied to detect M. leprae?
»	Can the same acid-fast stain used for Mycobacterium tuberculosis be used for the leprosy bacillus?
»	What are Virchow cells?
»	Is the lepromin skin test helpful in making a diagnosis of leprosy?
»	Is the neuropathy in lepromatous leprosy the same as that in diabetic neuropathy?
»	Describe a patient with advanced lepromatous leprosy.
»	What are the most common complications in leprosy?
»	What are the reactional states of leprosy?
»	What drugs are used in multidrug therapy for leprosy?
»	Do the recommendations of the World Health Organization (WHO) differ from those of the U.S.?
»	What are the side effects of the drugs for leprosy treatment?
»	What is the most bothersome cutaneous side effect of clofazimine?
»	How are the reactional states of leprosy treated?
»	Should family members of leprosy patients be treated?
»	Can leprosy be eliminated as a worldwide disease, as smallpox has been?

Do the recommendations of the World Health Organization (WHO) differ from those of the U.S.?

Due to economic and other factors, the WHO treatment recommendations are different from those of the U.S. The WHO multidrug therapy (MDT) recommends for multibacillary leprosy rifampin, 600 mg, and clofazimine, 300 mg once a month, and daily dapsone 100 mg and clofazimine 50 mg for 12 months. Paucibacillary leprosy is treated with dapsone, 100 mg/day, and rifampin, 600 mg/month for 6 months. Since 1995, WHO has provided free MDT for all leprosy patients worldwide.